Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Leon Kircik MD

Leon Kircik MD

Clinical Associate Professor of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Indiana University Medical Center, Indianapolis, Indiana

Dr. Kircik is a Board Certified Dermatologist who graduated with AOA Honors from State University of New York at the Health Sciences Center at Brooklyn after completing his undergraduate work with Phi Beta Kappa at New York University. He completed a Mohs Micrographic Surgery and Cutaneous Oncology Fellowship under the auspices of Dr. Frederick Mohs at the University of Wisconsin after completing his dermatology residency at State University of New York in Buffalo.

He currently teaches as Associate Clinical Professor of Dermatology at Indiana University Medical Center in Indianapolis, IN, and as Clinical Professor of Dermatology at Icahn School of Medicine at Mount Sinai Medical Center in New York City. Dr. Kircik is also the Medical Director of DermResearch, PLLC , Physicians Skin Care, PLLC and Skin Sciences, PLLC in Louisville, Kentucky. Dr Kircik is also the president and founder of International Dermatology Education Foundation (IDEF) which is a non- profit organization with the goal of promoting dermatologic disease awareness and education globally. He has been the principal investigator of numerous clinical trials for psoriasis, acne, rosacea, atopic dermatitis, skin cancers, and actinic keratosis, just to name a few.

Dr. Kircik is an author of many scientific articles, abstracts and posters. He has lectured extensively nationally and internationally on all aspects of dermatologic conditions. In addition, he also serves on the advisory boards of several pharmaceutical companies as a consultant. He is on the editorial board of Journal of Drugs in Dermatology, Practical Dermatology, The Journal of Clinical & Aesthetic Dermatology, and Case Report in Clinical Pathology. He volunteers for multiple local and national medical society committees.

Disclosures

Leon Kircik, MD Financial Disclosures:

Company Name

Type of Relationship

Nature of Compensation

Abbott Laboratories

 

Speaker

H

Aclaris

Advisory Board

H

Acambis

Investigator

G

Allergan, Inc.

Investigator

H

Advisory Board

H

Speaker

H

Consultant

H

Almirall

Consulting

H

Advisory Board

H

Amgen, Inc.

Consultant

H

Investigator

G

Speaker

H

Anacor Pharmaceuticals

Investigator

G

Consultant

H

Advisory Board

H

Assos Pharma

Speaker

H

Astellas Pharma US, Inc.

Investigator

G

Speaker

H

Asubio

Investigator

G

Berlex Laboratories (Bayer HealthCare Pharmaceuticals)

Investigator

G

Biogen-Idec

Advisory Board

H

Biolife

Investigator

G

Biopelle

         Investigator

G

Boehringer-Ingleheim

Investigator

G

Breckinridge Pharma

Investigator

G

Colbar

Consultant

H

Advisory Board

H

Celgene

Investigator

G

Advisory Board

H

Centocor, Inc.

Investigator

G

Cellceutix

Investigator

G

Cipher

Consultant

H

Speaker

H

Advisory Board

H

Coherus

Investigator

G

CollaGenex

Investigator

G

Consultant

H

Speaker

H

Combinatrix

Investigator

G

Connetics Corporation

Advisory Board

H

Consultant

H

Speaker

H

Investigator

G

Coria

Investigator

G

Dermavant

Investigator

H

Dermira

Investigator

G

Dermik Laboratories

Speaker

H

Dow Pharmaceutical Sciences, Inc.

 

Investigator

G

Dusa

Investigator

G

Embil Pharmaceuticals

Speaker

H

Eli Lilly

Investigator

G

EOS

Advisory Board

H

Exeltis

Advisory Board

H

Consultant

H

Speaker

H

Investigator

G

Ferndale Laboratories, Inc.

Advisory Board

H

Investigator

G

Foamix

Investigator

G

 

Advisory Board

H

 

Consultant

H

Speaker

H

Advisory Board

H

Investigator

G

Genentech, Inc.

 

Advisory Board

H

Speaker

H

Investigator

G

Consultant

H

GlaxoSmithKline, PLC

Investigator

G

Health Point, LTD

Investigator

G

Idera

Investigator

G

Intendis

Advisory Board

H

Consultant

H

Investigator

G

Innocutis

Speaker

H

Advisory Board

H

Innovail

Speaker

H

Isdin

Advisory Board

H

Consultant

H

Johnson & Johnson

Consultant

H

Investigator

G

Advisory Board

H

Speaker

H

Stockholder

 

Laboratory Skin Care Inc.

Consultant

H

Leo

Investigator

G

Consultant

H

Speaker

H

L’Oreal

Investigator

G

Speaker

H

3M

Speaker

H

Investigator

G

Maruho

Investigator

G

Medical International Technologies

Consultant

H

Merck

Consultant

H

Investigator

G

Medicis Pharmaceutical Corp.

Investigator

G

Merz

Consultant

H

Nano Bio

Advisory Board

H

Investigator

G

 

Novartis AG

 
 

 

Investigator

G

Consultant

H

Noven Pharmaceuticals

Investigator

G

Nucryst Pharmaceuticals Corp

Investigator

G

Obagi

Investigator

G

Onset

Investigator

G

Speaker

H

OrthoNeutrogena

Speaker

H

Investigator

G

Advisory Board

H

Consultant

H

Promius

Investigator

G

Consultant

H

Advisory Board

H

PediaPharma

Speaker

H

QLT, Inc.

Investigator

H

PharmaDerm

Investigator

G

Speaker

H

Pfizer

Investigator

G

PuraCap

Consultant

H

Quinnova

Investigator

H

Advisory Board

H

Quatrix

Investigator

G

Serono (Merck Serono International SA)

Speaker

H

SkinMedica, Inc.

Consultant

H

Investigator

G

Advisory Board

H

Speaker

H

Stiefel Laboratories, Inc.

Speaker

H

Investigator

G

Advisory Board

H

Consultant

H

Sun Pharma

Consultant

Advisory Board

Speaker

H

H

H

Investigator

G

Taro

Consultant/Speaker

H

TolerRx

Investigator

G

Triax

Speaker

H

UCB

Investigator

G

Consultant

H

Speaker

H

Valeant Pharmaceuticals Intl

Advisory Board

H

Investigator

G

Consultant

H

Valeant Pharmaceuticals Intl

Speaker

H

Warner-Chilcott

Advisory Board

H

Speaker

H

Investigator

G

XenoPort

Investigator

G

ZAGE

Consultant

H

Legend: G=grant; H=honorarium

Recent Contributions to PracticeUpdate:

  1. Clinical Characteristics of Patients With Psoriasis With a Family History of Psoriasis
  2. Clinical Outcomes of COVID-19 in Patients Taking Tumor Necrosis Factor Inhibitors and/or Methotrexate
  3. Modifiable Risk Factors and the Development of Psoriatic Arthritis in People With Psoriasis

Most Read This Week

Recently Updated